INBP — INTEGRATED BIOPHARMA INC
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1016504 ·
Last close
$0.18
Market Cap
$5.59M
52W High
$0.42
52W Low
$0.14
ADV30
5,343
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 9,796,000 | 28,000 | -869,000 | -1,366,000 | 25,338,000 | 4,471,000 | 7,671,000 |
| Mar 2026 | 10,107,000 | -276,000 | -1,085,000 | -837,000 | 26,669,000 | 5,826,000 | 7,687,000 |
| Dec 2025 | 11,280,000 | 29,000 | -914,000 | -762,000 | 23,547,000 | 5,314,000 | 3,779,000 |
| Sep 2025 | 12,689,000 | 1,019,000 | 163,000 | 123,000 | 25,540,000 | 4,732,000 | 5,051,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,241,000
Investing CF
$-340,000
Financing CF
$-45,000
CapEx
$-350,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.10
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-34,261,000
Inventory
$9,142,000
Receivables
$3,334,000
ST Investments
—
EBIT TTM
$-2,705,000
Pretax Income TTM
$-2,563,000
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$43,872,000
EBITDA
$-2,412,000
Free Cash Flow
$2,798,625
Enterprise Value
$4,312,650
Total Cash
$4,471,000
Total Debt
$3,078,000
Shares Out
31,059,610
Trailing EPS
$-0.09
Book Value
$0.57
ROE
-15.0%
ROA
-6.7%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 43,872,000 | -2,705,000 | -2,842,000 | 25,338,000 | 7,671,000 | 17,667,000 | 1,241,000 |
| Jun 2025 | 54,353,000 | 2,020,000 | 808,000 | 24,901,000 | 4,584,000 | 20,317,000 | 2,065,000 |
| Jun 2024 | 50,317,000 | 251,000 | 112,000 | 26,207,000 | 6,969,000 | 19,238,000 | 943,000 |
| Jun 2023 | 50,672,000 | 120,000 | -34,000 | 25,431,000 | 6,570,000 | 18,861,000 | 1,232,000 |
| Jun 2022 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$43,872,000
NetIncome TTM
$-2,842,000
OpCashFlow TTM
—
Assets (Latest)
$26,669,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AEON | AEON Biopharma, Inc. | $5.66M | $0.11 | — |
| OTLC | Oncotelic Therapeutics, Inc. | $5.72M | $0.01 | — |
| ALZN | Alzamend Neuro, Inc. | $5.45M | $1.13 | — |
| GTBP | GT Biopharma, Inc. | $5.74M | $3.18 | — |
| BLRX | BioLineRx Ltd. | $5.43M | $1.12 | — |
News headlines (Yahoo Finance, 1h cache)
Integrated BioPharma Reports Results for its Quarter Ended September 30, 2026
2026-11-13 17:05 · Yahoo
Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2026
2026-09-25 21:00 · Yahoo
Integrated BioPharma Reports Results for its Quarter Ended March 31, 2026
2026-05-08 20:30 · Yahoo
Integrated BioPharma Reports Results for Its Quarter Ended December 31, 2025
2026-02-11 21:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.